Paper41821152
Engineering MnPt Bimetallic Nanozymes for Cascade Enzymatic Therapy and Enhanced Radio-Immunotherapy.
Zhang W and 8 others. Adv Sci (Weinh), 2026. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Engineering MnPt Bimetallic Nanozymes for Cascade Enzymatic Therapy and Enhanced Radio-Immunotherapy. Papers, record 41821152. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41821152
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Engineering MnPt Bimetallic Nanozymes for Cascade Enzymatic Therapy and Enhanced Radio-Immunotherapy.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Platinum | Major topic |
| Radioimmunotherapy | Major topic |
| Manganese | Major topic |
| Immunotherapy | Major topic |
| Breast Neoplasms | Major topic |
| Animals | |
| Mice | |
| Humans | |
| Tumor Microenvironment | |
| Female | |
| Manganese Compounds | |
| cGAS-STING Signaling Pathway | |
| Cell Line, Tumor | |
| Hyaluronic Acid | |
| Oxides |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82272804 | National Natural Science Foundation of China | PubMed | ||
| 91959114 | National Natural Science Foundation of China | PubMed | ||
| 81872106 | National Natural Science Foundation of China | PubMed | ||
| 22JCQNJC01700 | Natural Science Foundation of Tianjin | PubMed | ||
| TJWJ2022XK015 | Scientific and Technological Research Program of Tianjin Health Commission | PubMed | ||
| TJYXZDXK-070C | Medical Key Discipline Program of Tianjin Municipal Healthcare Commission | PubMed |
Source PubMed
References58
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36848115 | Biomineralized MnO2 Nanoplatforms Mediated Delivery of Immune Checkpoint Inhibitors with STING Pathway Activation to Potentiate Cancer Radio-Immunotherapy. | ACS Nano | 2023 | https://conductscience.org/library/papers/36848115 | PubMed |
| 2 | 40367177 | Endogenous/exogenous dual-responsive nanozyme for photothermally enhanced ferroptosis-immune reciprocal synergistic tumor therapy. | Sci Adv | 2025 | https://conductscience.org/library/papers/40367177 | PubMed |
| 3 | 32239210 | Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival: Long-term Results From the TARGIT-A Randomized Clinical Trial in Early Breast Cancer. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/32239210 | PubMed |
| 4 | 38971872 | An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses. | Nat Commun | 2024 | https://conductscience.org/library/papers/38971872 | PubMed |
| 5 | 33009382 | Targeted scavenging of extracellular ROS relieves suppressive immunogenic cell death. | Nat Commun | 2020 | https://conductscience.org/library/papers/33009382 | PubMed |
| 6 | 38193384 | An Immunocompetent Hafnium Oxide-Based STING Nanoagonist for Cancer Radio-immunotherapy. | ACS Nano | 2024 | https://conductscience.org/library/papers/38193384 | PubMed |
| 7 | 38816668 | Signaling pathways in liver cancer: pathogenesis and targeted therapy. | Mol Biomed | 2024 | https://conductscience.org/library/papers/38816668 | PubMed |
| 8 | 39025943 | Radiotherapy-triggered reduction of platinum-based chemotherapeutic prodrugs in tumours. | Nat Biomed Eng | 2024 | https://conductscience.org/library/papers/39025943 | PubMed |
| 9 | 34099730 | Glucose-oxidase like catalytic mechanism of noble metal nanozymes. | Nat Commun | 2021 | https://conductscience.org/library/papers/34099730 | PubMed |
| 10 | 40525679 | Tumor Microenvironment-responsive Nanocatalyst for Targeted Chemodynamic Cancer Therapy. | Adv Healthc Mater | 2025 | https://conductscience.org/library/papers/40525679 | PubMed |
| 11 | 38777879 | The role of plasmacytoid dendritic cells (pDCs) in immunity during viral infections and beyond. | Cell Mol Immunol | 2024 | https://conductscience.org/library/papers/38777879 | PubMed |
| 12 | 38063844 | STING Agonist-Loaded Nanoparticles Promotes Positive Regulation of Type I Interferon-Dependent Radioimmunotherapy in Rectal Cancer. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/38063844 | PubMed |
| 13 | 39571173 | Oxygen/Nitric Oxide Dual-Releasing Nanozyme for Augmenting TMZ-Mediated Apoptosis and Necrosis. | Mol Pharm | 2025 | https://conductscience.org/library/papers/39571173 | PubMed |
| 14 | 32298077 | Manganese-Based Nanoactivator Optimizes Cancer Immunotherapy via Enhancing Innate Immunity. | ACS Nano | 2020 | https://conductscience.org/library/papers/32298077 | PubMed |
| 15 | 36038913 | Recent advances in therapeutic strategies for triple-negative breast cancer. | J Hematol Oncol | 2022 | https://conductscience.org/library/papers/36038913 | PubMed |
| 16 | 40386978 | Dendrimer-Entrapped CuPt Bimetallic Nanozymes for Tumor Microenvironment-Regulated Photothermal/Catalytic Therapy. | ACS Appl Mater Interfaces | 2025 | https://conductscience.org/library/papers/40386978 | PubMed |
| 17 | 41137633 | Proton-Driven Deformability Enables Nanozyme-Integrated Vaccine for Enhanced Tumor Immunotherapy. | Adv Mater | 2026 | https://conductscience.org/library/papers/41137633 | PubMed |
| 18 | 35874717 | Immunotherapy: Reshape the Tumor Immune Microenvironment. | Front Immunol | 2022 | https://conductscience.org/library/papers/35874717 | PubMed |
| 19 | 40810617 | Nanozyme-Based Biomimetic Intelligent Immune Organelles for the Treatment of Bladder-Metastasized Tumors. | Adv Mater | 2025 | https://conductscience.org/library/papers/40810617 | PubMed |
| 20 | 34166607 | Contemporary radiotherapy: present and future. | Lancet | 2021 | https://conductscience.org/library/papers/34166607 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42884170 | Nanoparticle-Enabled Immune-Dose Shaping in Breast Cancer Radiotherapy: Reconciling Tumor Immunogenicity with Systemic Immune Preservation. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42884170 | PubMed |
| 42195458 | Nanozyme-Driven Signal Amplification in Cancer Biosensing: Innovations Toward Precision and Point-of-Care Oncology. | Micromachines (Basel) | 2026 | https://conductscience.org/library/papers/42195458 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD44 | 960 | PubTator's text mining | https://conductscience.org/library/genes/960 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| CGAS | 115004 | PubTator's text mining | https://conductscience.org/library/genes/115004 | NCBI Gene |
| STING1 | 340061 | PubTator's text mining | https://conductscience.org/library/genes/340061 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41821152
GET https://conductscience.org/api/papers/v1/41821152/references?page=2